Pascual, Thomas N. B. http://orcid.org/0000-0001-6444-7803
Paez, Diana http://orcid.org/0000-0001-9268-0979
Iagaru, Andrei http://orcid.org/0000-0003-0839-5329
Gnanasegaran, Gopi http://orcid.org/0000-0002-4617-9013
Lee, Sze Ting http://orcid.org/0000-0001-8641-456X
Sathekge, Mike http://orcid.org/0000-0002-2806-0625
Buatti, John M. http://orcid.org/0000-0001-8499-3721
Giammarile, Francesco http://orcid.org/0000-0002-0550-7893
Al-Ibraheem, Akram http://orcid.org/0000-0002-0978-4716
Pardo, Manuela Arevalo
Baum, Richard P. http://orcid.org/0000-0003-1723-0075
De Bari, Berardino http://orcid.org/0000-0003-0117-3360
Ben-Haim, Simona http://orcid.org/0000-0002-6111-1826
Blay, Jean-Yves http://orcid.org/0000-0001-7190-120X
Brink, Anita http://orcid.org/0000-0001-8658-2379
Estrada-Lobato, Enrique http://orcid.org/0000-0002-2597-8609
Fanti, Stefano http://orcid.org/0000-0003-1486-2624
Golubic, Anja Tea http://orcid.org/0000-0002-1113-3840
Hatazawa, Jun http://orcid.org/0000-0003-1425-0521
Israel, Ora http://orcid.org/0000-0001-6545-0924
Kiess, Ana http://orcid.org/0000-0001-6928-3852
Knoll, Peter http://orcid.org/0000-0002-1249-922X
Louw, Lizette http://orcid.org/0000-0002-4146-2485
Mariani, Giuliano http://orcid.org/0000-0002-1900-4488
Mirzaei, Siroos http://orcid.org/0000-0003-2861-6811
Orellana, Pilar http://orcid.org/0000-0001-7743-5836
Prior, John O. http://orcid.org/0000-0003-1429-1374
Urbain, Jean-Luc
Vichare, Shrikant http://orcid.org/0009-0004-5854-0963
Vinjamuri, Sobhan http://orcid.org/0000-0003-3571-3273
Virgolini, Irene http://orcid.org/0000-0001-7097-6170
Scott, Andrew M. http://orcid.org/0000-0002-6656-295X
Funding for this research was provided by:
La Trobe University
Article History
Received: 11 December 2023
Accepted: 13 February 2024
First Online: 8 March 2024
Declarations
:
: AI reports scientific advisory boards for Alpha9Tx, Clarity Pharmaceuticals, Radionetics Oncology; research grants from GE Healthcare and Novartis; consulting with Novartis, Progenics Pharmaceuticals, and study steering committee for Novartis. GG has received speaker fee from Advanced Accelerator Application. RPB is an advisor to 3B Pharmaceuticals, ITM, Full Life Technologies, Sinotau, Jiangsu Huayi Technology, and Telix Pharmaceuticals. OI is a consultant for General Electric Healthcare. AK reports Institutional clinical research funding from Bayer, Novartis, Merck, and Lantheus; unpaid steering committee and advisory boards for Novartis; unpaid speaker (one event) for POINT. SV reports funding for educational lectures from Bayer, AAA/Novartis, Astellas. AMS reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; research funding from Medimmune, AVID Radiopharmaceuticals, Adalta, Antengene, Humanigen, Telix Pharmaceuticals and Theramyc; and advisory boards of Imagion and ImmunOs. The other authors report no relevant financial or non-financial interests to disclose.